So they just broke the $5 barrier.

[bradleysbest]

I wonder if the Tutes are still accumulating.....

[kball]

I wonder how many who hold from here end up purchasing more shares at double the cost from these prices once the herd helps confirm their thinking some time in the future?

When i need this money in 2020, I can't imagine sales and other products arent on line and going gangbusters

[jay1ajay1a]

I am picking up some more shares, but have a sick feeling. The someone I had when I paid my taxes.

[gomnkd]

let me share some of my thoughts. I based my views on seeing how other stocks perform when sales disappoint.

Look at how Theravance, Arena, Nektar etc perform when sales disappoint. It keeps dropping as speculators leave. It bottoms out. In several posts for last few weeks, I had mentioned that I'm surprised that stock is holding at these prices. In fact, every cell in my body was urging me to sell cov calls. I didn't and don't regret it. I want to see Sanofi/MNKD view in q calls.

I've been right twice about MNKD. After 2nd CRL, stock dropped to 6. I predicted further drops due to dilution. It went really low. I got out mostly between 5.5 & 6. Recently after approval, I sold 95% of stock ($9-10) and sold several hundred contracts to convert plain calls to spreads. All but strike 5 expired. I reentered at ~5.5 and haven't sold since. In short term, I got fooled by the supposed samples demand.

For some, my views appear grotesque. It is just one man's view. No reason to get agitated about it.


PS: My Price target was when we dont have any catalysts. i.e If you see 100-120 NRX until DTC starts

[Chris-C]

The hedgies dropped it this low before the adcom and then messed with it before approval. So these games have been played before and will be played repeatedly until strong sales materialize and a Technosphere partnership is announced. As other astute investors have observed, like the Chinese ying and yang, view it as threat or view it as opportunity.  Yet, despite the fact that this is a repeat of the same old tactics, there is the recurring drumbeat of critics and naysayers whose fantasies are not coming true according to their own optimistic schedules (based on what?). Somehow, I just have a hunch that the people at Sanofi and Mannkind know what they are doing. And guess what? If they are doing their jobs, they are not focused on the unrealistic needs of shareholders who imagined greater returns earlier.

Ultimately, the treatment paradigm for diabetes will change, because unless someone finds a surefire cure for diabetes, sedentary lifestyles, improper nutritional habits and obesity; the sad truth is that there will be lots more people with diabetes in the years ahead. And in all my investments that have taught me lessons,   I've allowed short driven FUD to scare me into parting with shares in companies I was certain would return value. The result is that in those cases I lost thousands of dollars of potential returns— All because I did not have the courage and tenacity to stick with my convictions. It will not happen again. Since I don't buy on margin and I don't invest money I can't afford to lose, the worst thing that can happen is that diabetics and practitioners are somehow deprived of a game changing medicine.

Using a realistic horizon, to me, regardless of the SP now, there is absolutely no cause for worry or the wringing of hands at this point. This is manipulation on no news. We have not even seen DTC advertisements yet and we do not know what the game plan is for targeting and educating providers. Will the companies reveal their sales strategy in the upcoming annual meeting? I rather doubt it. Why would they want to tip off the competition? I suspect there are some concerned pharmaceuticals out there looking at the numbers being reported in social media and scrambling to evade the inevitable Tsunami.

GLTA

Chris C

[me]

Apr 20, 2015 10:13:50 GMT -5 @fugacity said:

Apr 20, 2015 10:03:14 GMT -5 alethea said:

I wish I'd been a short and shared in their plentiful gains.

I'm not against people sharing their frustration, but the way some folks do it around here (some people I don't see post very often and when they do, hide behind the moniker of "objectivism"), I start to wonder about the difference between frustration and motive.

No one stopped any of you from riding purchased puts down to this point to protect your long investment. Neither company pulled the "wool over your eyes" stating anything other than a soft launch.

Truer words could not have been written.  And any "objective" person knows that the investing public always knows every single tactical and strategic plan, and every single projection that management has.  When you look at every "objective" comment on how poorly MNKD or SNY are doing with regard to Afrezza (or even Technosphere), all of them are based upon the fact that no one has sat down with the commenter and shared every internal data point and plan that exists.  Again, if you're going to invest (especially in pharma stocks), you need to understand basic business principles (unless your personal objective is spreading FUD).

[tripoley]

Apr 20, 2015 11:06:29 GMT -5 gomnkd said:

let me share some of my thoughts. I based my views on seeing how other stocks perform when sales disappoint.

When sales disappoint? Sales haven't even started. After SNY reps are out in full force pushing Afrezza, we see some ads in medical journals and endos are talking about Afrezza at physician conferences (plus or minus DTC), then we can discuss disappointing sales.

[bradleysbest]

Let's hope we close above $5 today!

[Deleted]

will this close flat for what it is ..lol?

[hankscorpio7]

Ahh, the $5 line in the sand has fallen. It was just a number.

Joy division comes to mind "love, love will tear us apart... again."
Gone too soon.